If you purchased Clover Health Investments, Corp. shares prior to February 4, 2021, and wish to join this litigation as a potential lead plaintiff, please complete the following Investor Certification [contact-form-7 id=”1693″ title=”Investigation of Clover Health Investments, Corp. NASDAQ: CLOV Investor Certification”]
The law firm of Federman & Sherwood has initiated an investigation into Clover Health Investments, Corp. [NASDAQ: CLOV] (“CLOV”) with respect to possible violations of federal securities laws.
On January 7, 2021, Clover merged with SPAC Social Capital Hedosphia Holdings Corp. III and began to trade under the symbol CLOV. On February 4, 2021, Hindenburg Research published a report about CLOV titled “Clover Health: How the “King of SPACs” Lured Retail Investors Into a Broken Business Facing an Active, Undisclosed DOJ Investigation.” The report alleged that Clover “has not disclosed that its business model and its software offering, called the Clover Assistant, are under active investigation by the Department of Justice (DOJ), which is investigating at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals[.]” The report further noted that “multiple former [Clover] employees explained that much of Clover’s sales are fueled by a major undisclosed relationship between Clover and an outside brokerage firm controlled by Clover’s Head of Sales, Hiram Bermudez.” On this news shares of Clover stock fell $1.72 per share to close at $12.23 per share on February 4, 2021.
If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact: Robin Hester at email@example.com